Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019163 (hepatitis B)
 38,309 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Hepatitis B infection is endemic in the tropics. Human immunodeficiency virus (HIV) infection might also be endemic in parts of Africa. Blood transfusion is a major risk factor in the transmission of either virus. Patients with end-stage chronic renal failure undergoing dialysis receive multiple blood transfusions. 3 of 12 hemodialyzed patients in a renal unit were found to carry the hepatitis B surface antigen. No patient on continuous ambulatory peritoneal dialysis and no patient with a kidney transplant bore that antigen. 5 of 12 hemodialyzed patients and only 1 of 7 on continuous ambulatory peritoneal dialysis were positive for the hepatitis B surface antibody. This status remained unchanged for 1 year. Only 1 patient who was initially HIV negative converted to HIV positive a year later.
 ...
PMID:Serological and epidemiological studies of hepatitis B and human immunodeficiency virus in a dialysis unit of Africa. 206 81

The prevalence of hepatitis C infection was evaluated (Ortho HCV Antibody ELISA Test) in 64 patients with chronic renal failure treated in a single hemodialysis unit. None of these patients was a carrier of hepatitis B virus nor of antibodies against human immunodeficiency virus. Antibodies against hepatitis C virus were detected in 11 patients (17%). The prevalence was higher in the 13 previously diagnosed of non A, non B hepatitis (77%) than in the 51 without previous hepatitis (2%) (p less than 0.001). A relationship between the infection rate and the number of previous blood transfusions was also observed: 5% in the patients without previous transfusions, 13% in the 30 patients who had received between 1 and 10 blood units and 40% in the 15 who had received more than 10 blood units (p less than 0.05). These data suggest that the hepatitis C virus may be responsible for most episodes previously diagnosed as non A, non B hepatitis, and that blood transfusions are the major risk factor.
 ...
PMID:[Hepatitis C virus infection in patients treated with hemodialysis]. 212 6

Only 50 to 60% of dialysis patients develop anti-HBs antibodies following hepatitis B vaccination. The nonresponder state correlates with impaired monocyte function, decreased interleukin-2 (IL-2) production of T cells, and an upregulation of the IL-2 receptor system. In the present study we examined anti-HBs production after hepatitis B vaccination and the in vitro expression of IL-2 receptors in nondialyzed patients with various degrees of chronic renal failure. Forty-four patients with impaired renal function were immunized with 2 micrograms recombinant hepatitis B vaccine and boostered after one and six months. Prior to the first injection IL-2 receptor expression of activated T cells was studied by an in vitro proliferation assay. Sixty-four healthy subjects served as controls. After completion of the third vaccination 55.0% of the patients acquired antibody titers greater than 10 U/liter. The seroconversion rate did not differ between patients with lower (less than 3.5 mg/dl) and higher (greater than 3.5 mg/dl) creatinine levels. In nonresponders IL-2 receptor expression (stimulation index, SI = 10.09 +/- 1.80) was elevated compared to healthy controls (SI = 4.62 +/- 0.35, P less than 0.002) or patients who responded with a high antibody titer (greater than 50 U/liter, SI = 3.12 +/- 0.43, P less than 0.001). Patients who produced low antibody titers (less than 50 U/liter) also presented with enhanced IL-2 receptor expression. These data show that an impaired antibody production following hepatitis B vaccination and an enhanced IL-2 receptor expression of T cells may already be present in early stages of chronic renal failure.
 ...
PMID:Hepatitis B vaccination and interleukin 2 receptor expression in chronic renal failure. 215 86

Antibody profiles for hepatitis B virus (HBV), hepatitis A virus (HAV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV) were determined on 55 serum samples collected from patients with chronic renal failure who were on long-term haemodialysis for periods ranging from 8 months to 5 years and 3 months. The exposure rates for HBV, HAV, CMV, EBV and HIV were 94.5%, 100%, 94.5%, 94.5% and 0% respectively. Among the 7 HBsAg carriers, 1 and 3 were positive for e antigen (HBeAg) and antibody to HBeAg (anti-HBe), respectively and three negative for both. These 7 carriers were also negative for anti-delta antibody. A comparison of the above antiviral profiles to those of voluntary blood donors and general population in this district revealed tht there is no difference for HBV, HAV, CMV and EBV exposure rates, VDRL, alpha-fetoprotein and CEA were also tested and the results showed no abnormalities. Only 3 patients had abnormally elevated SGOT and SGPT levels; the causes were undetermined because all of them gave positive HBV, HAV, CMV and EBV antibody profiles. In conclusion the screening of HBsAg and VDRL in the blood banks virtually eliminated possible infections of HBV and spirochate by blood transfusion and the patients with chronic renal failure who are maintained on long-term haemodialysis are generally not at higher risks of hepatitis-related viral infections.
 ...
PMID:[Hepatitis-related viral markers in patients under long-term hemodialysis]. 245 21

Hepatitis B remains a significant risk to patients receiving chronic hemodialysis, but no certain method of prevention has been identified. We tested two vaccines, plasma-derived vaccine (40-micrograms dose) and recombinant-derived vaccine (40-micrograms and 20-micrograms doses), in 61 patients with chronic renal failure who were not yet dependent on dialysis. Patients were followed up clinically and with laboratory tests of kidney function and hepatitis B virus serology for one year. Significantly more recipients of plasma-derived vaccine responded to vaccination; they also achieved a higher titer of antibody to hepatitis B virus than did recipients of recombinant-derived vaccine when evaluated at 6, 7, 9, and 12 mo after vaccination. No serious side effects were observed with any vaccine preparation, nor were excessive adverse effects observed in any group. Compared with the dialysis patients previously studied, patients with renal failure who were not yet dependent on dialysis responded more favorably to the hepatitis B virus vaccine.
 ...
PMID:Hepatitis B vaccines in patients with chronic renal failure before dialysis. 296 18

Hepatitis B markers were determined in patients with chronic renal failure and in staff members prior to entry into the hemodialysis unit of a hospital in southern Israel, an area in which hepatitis B is endemic. Patients and staff who were negative for hepatitis B markers were followed for a mean of 26.7 and 29.2 months, respectively, between November 1975 and May 1984. New infections occurred in 25.9% of the patients and 17.3% of the staff; the difference was not statistically significant. Hepatitis B markers were found in 26% of the staff and 41% of the patients (p less than 0.05) prior to their entry into the hemodialysis unit. Furthermore, in the patients, a relatively high rate of carriers was detected (7% compared with 2% in the general population), while no carriers were detected among the staff members. Within the staff group, nurses were at particularly high risk for new infections, accounting for seven of the nine (78%) events recorded. The high risk for the nursing staff is probably due to greater exposure to blood among nurses compared with other staff members.
 ...
PMID:Hepatitis B infections in a chronic hemodialysis unit in a country where hepatitis B is endemic: a prospective study. 361 82

A case report of a renal (mixed) cell carcinoma found in a 35-year-old male with acquired renal polycystosis who had died from chronic renal insufficiency treated with chronic hemodialysis is presented. The morphogenesis and pathogenesis of acquired polycystic transformation of the kidneys in patients with chronic renal failure and the possible relation of the former to renal cell carcinoma are discussed. A preblastomogenic role is suggested for sclerotic changes arising in polycystic kidneys as well as for hepatitis B virus which may act as an oncogene.
 ...
PMID:[Renal cell cancer in a polycystic kidney]. 366 50

Among 54 patients, between 2 and 18 years of age, submitted to hemodialysis due to severe chronic renal failure, the prevalence of hepatitis B virus markers was 66.7% and that of HBsAg was 13.0%. Eighteen children, with no evidence of hepatitis B virus infection, were vaccinated. Following three vaccine injections, only 2 patients did not respond and a third one developed low anti-HBs titers. The vaccine was well tolerated. No relationship was observed between the intensity of the humoral immune response and age, sex, type of renal disease and time on dialysis. Seroconversion rates (87.5%) and geometric means of anti-HBs titers (greater than 4 000 Ausab Units) of these patients are similar to those observed following vaccination of healthy adults.
 ...
PMID:Hepatitis B virus infection and vaccination in children undergoing hemodialysis. 399 67

During a study of peripheral nerve function in chronic renal failure, 11 patients who were being treated by chronic intermittent haemodialysis developed serum hepatitis. Before the infection there was a trend towards improvement in nerve conduction velocities. A pronounced deterioration in the conduction velocities in motor fibres of peripheral nerves occurred in association with hepatitis. In the months after recovery from the infection there was again a trend towards improvement in conduction velocities. We suggest that this reflects the occurrence of a peripheral neuropathy which is at least in part demyelinating. The neuropathy is related to the serum hepatitis, but its pathogenesis is indeterminate.
 ...
PMID:Neuropathy associated with hepatitis in patients maintained on haemodialysis. 433 84

Hepatitis B virus (HBV) markers have been studied for 22 months in 16 haemodialysed patients, 60 relatives and 17 staff members of a paediatric haemodialysis unit, and in 9 children with chronic renal failure on conservative therapy. None of the 8 children negative for HBV markers and treated with specific immunoglobulins (HBIG) developed signs of hepatitis B. No hepatitis B occurred in 4 staff members after accidental infected needle prick and immunoprophylaxis, although one of them developed passive-active immunity. The immunoprophylaxis effectively prevented diffusion of HBV also in the relatives. Furthermore, HBsAg and HBeAg were found in urine samples of haemodialysed children with residual diuresis.
 ...
PMID:Hepatitis B prevalence and immunoprophylaxis with hepatitis B immunoglobulins in patients, relatives, and staff of a paediatric haemodialysis unit. 708 27


<< Previous 1 2 3 4 5 6 7 8 9 Next >>